Gastrointestinal malignancies evaluated with 18F-fluoro-2-deoxyglucose positron emission tomography

Best Practice and Research: Clinical Gastroenterology

Volumn 20, Issue 1, 2006, Pages 3-21

  Chin, Bennett B ^a   Chang, Paul P L ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

Colorectal cancer; Computed tomography; Esophageal cancer; Fluorodeoxyglucose; Gastrointestinal neoplasms; Positron emission tomography; Review

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADENOCARCINOMA; BILE DUCT CARCINOMA; CANCER RECURRENCE; CANCER RELAPSE; CANCER STAGING; CLINICAL PRACTICE; CLINICAL TRIAL; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIGESTIVE SYSTEM CANCER; DISEASE MARKER; EARLY DIAGNOSIS; ESOPHAGUS CARCINOMA; GASTROINTESTINAL STROMAL TUMOR; HEALTH CARE COST; HUMAN; LIVER CELL CARCINOMA; METASTASIS; PANCREAS CARCINOMA; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PROGNOSIS; RELIABILITY; REVIEW; SENSITIVITY AND SPECIFICITY; SQUAMOUS CELL CARCINOMA; STOMACH CARCINOMA;

CLINICAL TRIALS; FLUORODEOXYGLUCOSE F18; GASTROINTESTINAL NEOPLASMS; HUMANS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 32244441615     PISSN: 15216918     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bpg.2005.08.001     Document Type: Review

References (108)

1. R.H. Huebner K.C. Park J.E. Shepherd et al. A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer J Nucl Med 41 7 2000 1177-1189
2. V. Kalff R.J. Hicks R.E. Ware et al. The clinical impact of 18F-FDG PET in patients with suspected or confirmed recurrence of colorectal cancer: a prospective study J Nucl Med 43 4 2002 492-499
3. B. Topal P. Flamen R. Aerts et al. Clinical value of whole-body positron emission tomography in potentially curable colorectal liver metastases Eur J Surg Oncol 27 2 2001 175-179
4. T.J.M. Ruers B.S. Langenhoff N. Neeleman et al. Value of positron emission tomography with [F-18] Fluorodeoxyglucose in patients with colorectal liver metastases: A prospective study J Clin Oncol 20 2 2002 388-395
5. T. Ruers R.P. Bleichrodt Treatment of liver metastases, an update on the possibilities and results Eur J Cancer 38 7 2002 1023-1033
6. T. Arulampalam D. Costa D. Visvikis et al. The impact of FDG-PET on the management algorithm for recurrent colorectal cancer Eur J Nucl Med 28 12 2001 1758-1765
7. T.H. Arulampalam D.C. Costa J.B. Bomanji P.J. Ell The clinical application of positron emission tomography to colorectal cancer management Q J Nucl Med 45 3 2001 215-230
8. P. Flamen Positron emission tomography in colorectal cancer Best Pract Res Clin Gastroenterol 16 2 2002 237-251
9. P. Flamen S. Stroobants E. Van Cutsem et al. Additional value of whole-body positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D-glucose in recurrent colorectal cancer J Clin Oncol 17 3 1999 894
10. D. Delbeke J.V. Vitola M.P. Sandler et al. Staging recurrent metastatic colorectal carcinoma with PET J Nucl Med 38 8 1997 1196-1201
11. J. Meta M. Seltzer C. Schiepers et al. Impact of 18F-FDG PET on managing patients with colorectal cancer: The referring physician's perspective J Nucl Med 42 4 2001 586-590
12. P.E. Valk E. Abella-Columna M.K. Haseman et al. Whole-body PET imaging with [18F]Fluorodeoxyglucose in management of recurrent colorectal cancer Arch Surg 134 5 1999 503-511
13. L. Staib H. Schirrmeister S.N. Reske H.G. Beger Is 18F-fluorodeoxyglucose positron emission tomography in recurrent colorectal cancer a contribution to surgical decision making? Am J Surg 180 1 2000 1-5
14. S.M. Strasberg F. Dehdashti B.A. Siegel et al. Survival of patients evaluated by FDG-PET before hepatic resection for metastatic colorectal carcinoma: A prospective database study Ann Surg 233 3 2001 293-299
15. M.H. Whiteford H.M. Whiteford L.F. Yee et al. Usefulness of FDG-PET scan in the assessment of suspected metastatic or recurrent adenocarcinoma of the colon and rectum Dis Colon Rectum 43 6 2000 759-767
16. S.N. Reske J. Kotzerke FDG-PET for clinical use. Results of the third German interdisciplinary consensus conference, 'Onko-PET III', 21 July and 19 September 2000 Eur J Nucl Med 28 11 2001 1707-1723
17. H. Abdel-Nabi R.J. Doerr D.M. Lamonica et al. Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET: Correlation with histopathologic and CT findings Radiology 206 3 1998 755-760
18. D. Delbeke W.H. Martin M.P. Sandler et al. Evaluation of benign vs malignant hepatic lesions with positron emission tomography Arch Surg 133 5 1998 510-515
19. L. Max R. Abdel-Malek D. Roger et al. FDG-PET improves the staging and selection of patients with recurrent colorectal cancer Eur J Nucl Med Mol Imaging 29 7 2002 915-921
20. F.L.M. Flanagan F.M. Dehdashti O.A.F. Ogunbiyi et al. Utility of FDG-PET for investigating unexplained plasma CEA elevation in patients with colorectal cancer. [Miscellaneous] Ann Surg 1998
21. P. Flamen O.S. Hoekstra F. Homans et al. Unexplained rising carcinoembryonic antigen (CEA) in the postoperative surveillance of colorectal cancer: The utility of positron emission tomography (PET) Eur J Cancer 37 7 2001 862-869
22. S.K. Libutti H.R. Alexander Jr P. Choyke et al. A prospective study of 2- [18F] fluoro-2-deoxy-D-glucose/positron emission tomography scan, 99mTc-labeled arcitumomab (CEA-scan), and blind second-look laparotomy for detecting colon cancer recurrence in patients with increasing carcinoembryonic antigen levels Ann Surg Oncol 8 10 2001 779-786
23. M. Selzner T.F. Hany P. Wildbrett et al. Does the novel PET/CT imaging modality impact on the treatment of patients with metastatic colorectal cancer of the liver? Ann Surg 240 6 2004 1027-1034
24. C. Cohade M. Osman J. Leal R.L. Wahl Direct comparison of 18F-FDG PET and PET/CT in patients with colorectal carcinoma J Nucl Med 44 11 2003 1797-1803
25. E. Even-Sapir Y. Parag H. Lerman et al. Detection of recurrence in patients with rectal cancer: PET/CT after abdominoperineal or anterior resection Radiology 232 3 2004 815-822
26. A. Turlakow H.W. Yeung A.S. Salmon et al. Peritoneal carcinomatosis: role of 18F-FDG PET J Nucl Med 44 9 2003 1407-1412
27. G. Antoch N. Saoudi H. Kuehl et al. Accuracy of whole-body dual-modality fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: comparison with CT and PET J Clin Oncol 22 21 2004 4357-4368
28. R. Patrick W. Franz-Josef S. Wolfram et al. Side-by-side reading of PET and CT scans in oncology: Which patients might profit from integrated PET/CT? Eur J Nucl Med Mol Imaging 31 11 2004 1456-1461
29. R. Bar-Shalom N. Yefremov L. Guralnik et al. Clinical performance of PET/ CT in evaluation of cancer: Additional value for diagnostic imaging and patient management J Nucl Med 44 8 2003 1200-1209
30. T.F. Hany H.C. Steinert G.W. Goerres et al. PET diagnostic accuracy: improvement with in-line PET-CT system: Initial results Radiology 225 2 2002 575-581
31. I.R. Kamel C. Cohade E. Neyman et al. Incremental value of CT in PET/CT of patients with colorectal carcinoma Abdom Imaging 29 6 2004 663-668
32. S. Yasuda H. Fujii T. Nakahara et al. 18F-FDG PET detection of colonic adenomas J Nucl Med 42 7 2001 989-992
33. J.P. Drenth F.M. Nagengast W.J.G. Oyen Evaluation of (pre-)malignant colonic abnormalities: Endoscopic validation of FDG-PET findings Eur J Nucl Med Mol Imaging 28 12 2001 1766-1769
34. E.M. Kamel M. Thumshirn K. Truninger et al. Significance of incidental 18F-FDG accumulations in the gastrointestinal tract in PET/CT: correlation with endoscopic and histopathologic results J Nucl Med 45 11 2004 1804-1810
35. K.C. Park J. Schwimmer J.E. Shepherd et al. Decision analysis for the cost-effective management of recurrent colorectal cancer Ann Surg 233 3 2001 310-319
36. C. Schiepers K. Haustermans K. Geboes et al. The effect of preoperative radiation therapy on glucose utilization and cell kinetics in patients with primary rectal carcinoma Cancer 85 4 1999 803-811
37. U. Haberkorn L.G. Strauss A. Dimitrakopoulou et al. PET studies of fluorodeoxyglucose metabolism in patients with recurrent colorectal tumors receiving radiotherapy J Nucl Med 32 8 1991 1485-1490
38. J.G. Guillem J. Puig-La Calle Jr T. Akhurst et al. Prospective assessment of primary rectal cancer response to preoperative radiation and chemotherapy using 18-fluorodeoxyglucose positron emission tomography Dis Colon Rectum 43 1 2000 18-24
39. F.A. Calvo M. Domper R. Matute et al. 18F-FDG positron emission tomography staging and restaging in rectal cancer treated with preoperative chemoradiation Int J Radiat Oncol Biol Phys 58 2 2004 528-535
40. M. Findlay H. Young D. Cunningham et al. Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: Correlation with tumor response to fluorouracil J Clin Oncol 14 3 1996 700-708
41. J.V. Vitola D. Delbeke S.G. Meranze et al. Positron emission tomography with F-18-fluorodeoxyglucose to evaluate the results of hepatic chemoembolization Cancer 78 10 1996 2216-2222
42. Y. Nagata K. Yamamoto M. Hiraoka et al. Monitoring liver tumor therapy with [18F] FDG positron emission tomography J Comput Assist Tomogr 14 3 1990 370-374
43. CyO Wong R. Salem F. Qing et al. Metabolic response after intraarterial 90Y-glass microsphere treatment for colorectal liver metastases: comparison of quantitative and visual analyses by 18F-FDG PET J Nucl Med 45 11 2004 1892-1897
44. G. Antoch G.M. Kaiser A.B. Mueller et al. Intraoperative radiation therapy in liver tissue in a pig model: Monitoring with dual-modality PET/CT Radiology 230 3 2004 753-760
45. Y. Fong P.F. Saldinger T. Akhurst et al. Utility of 18F-FDG positron emission tomography scanning on selection of patients for resection of hepatic colorectal metastases Am J Surg 178 4 1999 282-287
46. A. Suzuki T. Kawano N. Takahashi et al. Value of 18F-FDG PET in the detection of peritoneal carcinomatosis Eur J Nucl Med Mol Imaging 31 10 2004 1413-1420
47. H.L. van Westreenen M. Westerterp P.M.M. Bossuyt et al. Systematic review of the staging performance of 18F-fluorodeoxyglucose positron emission tomography in esophageal cancer J Clin Oncol 22 18 2004 3805-3812
48. P.A. Heeren P.L. Jager F. Bongaerts et al. Detection of distant metastases in esophageal cancer with (18)F-FDG PET J Nucl Med 45 6 2004 980-987
49. F.L. Flanagan F. Dehdashti B.A. Siegel et al. Staging of esophageal cancer with 18F-fluorodeoxyglucose positron emission tomography AJR Am J Roentgenol 168 2 1997 417-424
50. M.I. Block G.A. Patterson R.S. Sundaresan et al. Improvement in staging of esophageal cancer with the addition of positron emission tomography Ann Thorac Surg 64 3 1997 770-776
51. J.Y. Choi K.H. Lee Y.M. Shim et al. Improved detection of individual nodal involvement in squamous cell carcinoma of the esophagus by FDG PET J Nucl Med 41 5 2000 808-815
52. H. Kato T. Miyazaki M. Nakajima et al. The incremental effect of positron emission tomography on diagnostic accuracy in the initial staging of esophageal carcinoma Cancer 103 1 2005 148-156
53. P. Flamen A. Lerut E. Van Cutsem et al. Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma J Clin Oncol 18 18 2000 3202-3210
54. P. Flamen A. Lerut E. Van Cutsem et al. Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma J Clin Oncol 18 18 2000 3202-3210
55. P.A.M. Heeren P.L. Jager F. Bongaerts et al. Detection of distant metastases in esophageal cancer with 18F-FDG PET J Nucl Med 45 6 2004 980-987
56. Y.C. Yoon K.S. Lee Y.M. Shim et al. Metastasis to regional lymph nodes in patients with esophageal squamous cell carcinoma: CT versus FDG PET for presurgical detection prospective study Radiology 227 3 2003 764-770
57. W.A. Weber K. Ott K. Becker et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging J Clin Oncol 19 12 2001 3058-3065
58. B.L.D.M. Brucher W.M. Weber M.M. Bauer et al. Neoadjuvant therapy of esophageal squamous cell carcinoma: Response evaluation by positron emission tomography Ann Surg 233 3 2001 300-309
59. P. Flamen E. Van Cutsem A. Lerut et al. Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer Ann Oncol 13 3 2002 361-368
60. S.G. Swisher M. Maish J.J. Erasmus et al. Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer Ann Thorac Surg 78 4 2004 1152-1160
61. H.A. Wieder B.L.D.M. Brucher F. Zimmermann et al. Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment J Clin Oncol 22 5 2004 900-908
62. R.J. Downey T. Akhurst D. Ilson et al. Whole body 18FDG-PET and the response of esophageal cancer to induction therapy: Results of a prospective trial J Clin Oncol 21 3 2003 428-432
63. O. Vrieze K. Haustermans W. De Wever et al. Is there a role for FGD-PET in radiotherapy planning in esophageal carcinoma? Radiother Oncol 73 3 2004 269-275
64. M. Zimny R. Bares J. Fass et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in the differential diagnosis of pancreatic carcinoma: A report of 106 cases Eur J Nucl Med Mol Imaging 24 6 1997 678-682
65. D.M. Rose D. Delbeke R.D. Beauchamp et al. 18Fluorodeoxyglucose-positron emission tomography in the management of patients with suspected pancreatic cancer Ann Surg 229 5 1999 729-737
66. C.G. Diederichs L. Staib G. Glatting et al. FDG PET: Elevated plasma glucose reduces both uptake and detection rate of pancreatic malignancies J Nucl Med 39 6 1998 1030-1033
67. C. Sperti C. Pasquali F. Chierichetti et al. Value of 18-fluorodeoxyglucose positron emission tomography in the management of patients with cystic tumors of the pancreas Ann Surg 234 5 2001 675-680
68. M.T. Keogan D. Tyler L. Clark et al. Diagnosis of pancreatic carcinoma: role of FDG PET Am J Roentgenol 171 6 1998 1565-1570
69. H. Jadvar A.J. Fischman Evaluation of pancreatic carcinoma with FDG PET Abdom Imaging 26 3 2001 254-259
70. R. Bares P. Klever S. Hauptmann et al. F-18 fluorodeoxyglucose PET in vivo evaluation of pancreatic glucose metabolism for detection of pancreatic cancer Radiology 192 1 1994 79-86
71. J.C. Stollfuss G. Glatting H. Friess et al. 2-(fluorine-18)-fluoro-2-deoxy-D-glucose PET in detection of pancreatic cancer: Value of quantitative image interpretation Radiology 195 2 1995 339-344
72. H. Friess J. Langhans M. Ebert et al. Diagnosis of pancreatic cancer by 2 [18F]-fluoro-2-deoxy-D-glucose positron emission tomography [published erratum appears in Gut Sep;37(3):448] Gut 36 5 1995 771-777
73. A. Sendler N. Avril H. Helmberger et al. Preoperative evaluation of pancreatic masses with positron emission tomography using 18F-fluorodeoxyglucose: Diagnostic limitations World J Surg 24 9 2000 1121-1129
74. A. Sundin B. Eriksson M. Bergstrom et al. PET in the diagnosis of neuroendocrine tumors. Gastroenteropancreatic neuroendocrine tumor disease Mol Cell Biol Aspects 1014 2004 246-257
75. E. Bombardieri M. Maccauro E. De Deckere et al. Nuclear medicine imaging of neuroendocrine tumours Ann Oncol 12 Supplement 2 2001 S51-S61
76. D.S. Paul Focal fluorine-18 fluorodeoxyglucose accumulation in inflammatory pancreatic disease Eur J Nucl Med Mol Imaging 25 3 1998 259-264
77. Y. Nakamoto T. Higashi H. Sakahara et al. Delayed (18)F-fluoro-2-deoxy-D-glucose positron emission tomography scan for differentiation between malignant and benign lesions in the pancreas Cancer 89 12 2000 2547-2554
78. T. Higashi T. Saga Y. Nakamoto et al. Relationship between retention index in dual-phase 18F-FDG PET, and hexokinase-II and glucose transporter-1 expression in pancreatic cancer J Nucl Med 43 2 2002 173-180
79. E.U. Nitzsche S. Hoegerle M. Mix et al. Non-invasive differentiation of pancreatic lesions: Is analysis of FDG kinetics superior to semiquantitative uptake value analysis? Eur J Nucl Med Mol Imaging 29 2 2002 237-242
80. A.J. Lemke S.M. Niehues N. Hosten et al. Retrospective digital image fusion of multidetector CT and 18F-FDG PET: Clinical value in pancreatic lesions - a prospective study with 104 patients J Nucl Med 45 8 2004 1279-1286
81. A. Frohlich C.G. Diederichs L. Staib et al. Detection of liver metastases from pancreatic cancer using FDG PET J Nucl Med 40 2 1999 250-255
82. M. Yoshioka T. Sato T. Furuya et al. Role of positron emission tomography with 2-deoxy-2- [18F]fluoro-D-glucose in evaluating the effects of arterial infusion chemotherapy and radiotherapy on pancreatic cancer J Gastroenterol 39 1 2004 50-55
83. N.R. Maisey A. Webb G.D. Flux et al. FDG-PET in the prediction of survival of patients with cancer of the pancreas: A pilot study Br J Cancer 83 3 2000 287-293
84. M.A. Khan C.S. Combs E.M. Brunt et al. Positron emission tomography scanning in the evaluation of hepatocellular carcinoma J Hepatol 32 5 2000 792-797
85. T. Torizuka N. Tamaki T. Inokuma et al. In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET J Nucl Med 36 10 1995 1811-1817
86. S. Shiomi S. Nishiguchi H. Ishizu et al. Usefulness of positron emission tomography with fluorine-18-fluorodeoxyglucose for predicting outcome in patients with hepatocellular carcinoma Am J Gastroenterol 96 6 2001 1877-1880
87. M. Sugiyama H. Sakahara T. Torizuka et al. 18F-FDG PET in the detection of extrahepatic metastases from hepatocellular carcinoma J Gastroenterol 39 10 2004 961-968
88. C.L. Ho S.C. Yu D.W. Yeung 11C-acetate PET imaging in hepatocellular carcinoma and other liver masses J Nucl Med 44 2 2003 213-221
89. T. Torizuka N. Tamaki T. Inokuma et al. Value of fluorine-18-FDG-PET to monitor hepatocellular carcinoma after interventional therapy J Nucl Med 35 12 1994 1965-1969
90. T. De Potter P. Flamen E. Van Cutsem et al. Whole-body PET with FDG for the diagnosis of recurrent gastric cancer Eur J Nucl Med Mol Imaging 29 4 2002 525-529
91. A.C. Kole J.T. Plukker O.E. Nieweg W. Vaalburg Positron emission tomography for staging of oesophageal and gastroesophageal malignancy Br J Cancer 78 4 1998 521-527
92. T. Kawamura T. Kusakabe T. Sugino et al. Expression of glucose transporter-1 in human gastric carcinoma: Association with tumor aggressiveness, metastasis, and patient survival Cancer 92 3 2001 634-641
93. T. Yoshioka K. Yamaguchi K. Kubota et al. Evaluation of 18F-FDG PET in patients with advanced metastatic, or recurrent gastric cancer J Nucl Med 44 5 2003 690-699
94. K. Ott U. Fink K. Becker et al. Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: Results of a prospective trial J Clin Oncol 21 24 2003 4604-4610
95. A. Stahl K. Ott W.A. Weber et al. FDG PET imaging of locally advanced gastric carcinomas: Correlation with endoscopic and histopathological findings Eur J Nucl Med Mol Imaging 30 2 2003 288-295
96. E. Mochiki H. Kuwano H. Katoh et al. Evaluation of 18F-2-deoxy-2-fluoro-D-glucose positron emission tomography for gastric cancer World J Surg 28 3 2004 247-253
97. G.W. Goerres R. Stupp G. Barghouth et al. The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours: long-term outcome of treatment with imatinib mesylate Eur J Nucl Med Mol Imaging 32 2 2005 153-162
98. H. Choi C. Charnsangavej Sd.C. Faria et al. CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: A quantitative analysis correlated with FDG PET findings Am J Roentgenol 183 6 2004 1619-1628
99. G. Antoch J. Kanja S. Bauer et al. Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors J Nucl Med 45 3 2004 357-365
100. R. Kluge F. Schmidt K. Caca et al. Positron emission tomography with [(18)F]fluoro-2-deoxy-D-glucose for diagnosis and staging of bile duct cancer Hepatology 33 5 2001 1029-1035
101. S. Keiding S.B. Hansen H.H. Rasmussen et al. Detection of cholangiocarcinoma in primary sclerosing cholangitis by positron emission tomography Hepatology 28 3 1998 700-706
102. A. Fritdcher-Ravents K.H. Bohuslaviziki D. Broering et al. FDG PET in the diagnosis of hilar cholangiocarcinoma Nucl Med Commun 22 12 2001 1277-1285
103. J.D. Hainsworth F.A. Greco Drug-therapy - treatment of patients with cancer of an unknown primary site N Engl J Med 329 4 1993 257-263
104. R.C. Delgado-Bolton C. Fernandez-Perez A. Gonzalez-Mate et al. Meta-analysis of the performance of 18F-FDG PET in primary tumor detection in unknown primary tumors J Nucl Med 44 8 2003 1301-1314
105. U. Joshi J.J. van der Hoeven E.F. Comans et al. In search of an unknown primary tumour presenting with extracervical metastases: The diagnostic performance of FDG-PET Br J Radiol 77 924 2004 1000-1006
106. K.E. Rusthoven M. Koshy A.C. Paulino The role of fluorodeoxyglucose positron emission tomography in cervical lymph node metastases from an unknown primary tumor Cancer 101 11 2004 2641-2649
107. C. Nanni D. Rubello P. Castellucci et al. Role of (18)F-FDG PET-CT imaging for the detection of an unknown primary tumour: Preliminary results in 21 patients Eur J Nucl Med Mol Imaging 2005 [published online February 2005]
108. A. Gutzeit G. Antoch H. Kuhl et al. Unknown primary tumors: Detection with dual-modality PET/CT - initial experience Radiology 234 1 2005 227-234